ACM-001 / ACM Biolabs - LARVOL DELTA

Enhanced immunostimulatory and anti-tumor activity of TLR agonists encapsulated within ACM polymersomes (CRI-ENCI-AACR ICIC 2024) - P1 | "A recently completed phase 1 clinical trial (ClinicalTrials.gov identifier: NCT05385991) of ACM-CpG 7909 as an adjuvant for a SARS-CoV-2 booster vaccine (ACM-001) showed that it was well tolerated and induced good efficacy signals. An investigator-initiated dose-escalation/expansion trial to examine the safety and efficacy of ACM-CpG 7909 in patients with advanced/metastatic solid tumors is being planned at the National Cancer Center Singapore."

Infectious Disease • Novel Coronavirus Disease • Oncology • Respiratory Diseases • Solid Tumor • CD4 • CD8 • IFNA1 • IFNG • IL10 • IL1R1 • IL6

Amphiphilic Block Copolymer Nanostructures as a Tunable Delivery Platform: Perspective and Framework for the Future Drug Product Development. (PubMed, Biomacromolecules) - "For example, a COVID booster vaccine comprising polymersomes encapsulating spike protein (ACM-001) has recently completed a Phase I clinical trial and provides a case for developing safe drug products based on ABCP delivery platforms. However, several limitations need to be resolved before they can reach their full potential. In this Perspective, we would like to highlight such aspects requiring further development for translating an ABCP-based delivery platform from a proof of concept to a viable commercial product."

Journal • Review • Novel Coronavirus Disease

Booster Dose Study to Assess the Safety and Immunogenicity of ACM-001 Administered Intramuscularly or Intranasally. (clinicaltrials.gov) - P1 | N=38 | Completed | Sponsor: ACM Biolabs | Active, not recruiting ➔ Completed | Trial completion date: Dec 2023 ➔ Aug 2023

Trial completion • Trial completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Booster Dose Study to Assess the Safety and Immunogenicity of ACM-001 Administered Intramuscularly or Intranasally. (clinicaltrials.gov) - P1 | N=38 | Active, not recruiting | Sponsor: ACM Biolabs | Recruiting ➔ Active, not recruiting | N=80 ➔ 38 | Trial primary completion date: Dec 2022 ➔ Jun 2023

Enrollment change • Enrollment closed • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Booster Dose Study to Assess the Safety and Immunogenicity of ACM-001 Administered Intramuscularly or Intranasally. (clinicaltrials.gov) - P1 | N=80 | Recruiting | Sponsor: ACM Biolabs | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases